## **REMARKS**

Claims 28-49 are pending in the present application and have been allowed. Claims 28 and 39 have been amended to delete an unnecessary limitation, *i.e.*, that the subtilisin must be purified.

The specification has been amended to delete the remaining references to the protease derived from *Aspergillus sp.* CBS 102448. Applicants also enclose a set of formal drawings (six sheets). The new figures are identical to the originally-filed figures except that all references to the protease derived from *Aspergillus sp.* CBS 102448 have been deleted in Figures 4-6. As mentioned in the Amendment filed May 25, 2004, after the filing of the instant application, it was discovered that the results presented in the specification for this protease were not correct due to an impurity contained in the protease sample.

It is respectfully submitted that the present amendment presents no new issues or new matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: March 14, 2005

Elias J. Lambirs, Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097